In the specific case of chemically-induced Alzheimer’s disease, the integration of transcriptomic and proteomic data changes with biomarkers such as phosphorylated tau (p-tau) or NfL is now enabling predictive models concerning clinical outcomes [253]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.